Skip to content
value.today
Benitec Biopharma Inc. logo

Benitec Biopharma Inc.

BNTC
$307 Mmarket cap on Oct 29, 2026+3737.1% since Jan 2024
Compare
World rank
#14,684
Revenue
—
For year ending June-2026
Net income
$-46 M
SEC filing
Employees
—

Benitec Biopharma Inc. in brief

Benitec Biopharma Inc. is a listed company in the Biotechnology industry, based in Hayward, California, USA. It was founded in 1997. Its market value was $307 M on 29 October 2026, which makes it the 14,684th largest listed company in the world and the 2,861st largest in the USA on this site. Jerel A. Banks is its chief executive. Its shares trade under the symbol BNTC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Benitec Biopharma Inc.

Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.

The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Benitec Biopharma Inc. timeline

3 events, 1997–2020
  1. 1997
  2. 🏁
    · approximate
    Founded
  3. 2015
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2020
  6. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Benitec Biopharma Inc. from Wikidata, the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$116 M$233 M$349 M$465 M2020202120222023202420252026

World rank over time

▲ up 12,144 places since 2020
2020-01-01: #26864#26,86420202022-01-07: #30557#30,55720222022-12-25: #32925#32,92520222023-07-30: #22368#22,36820232024-01-05: #31701#31,70120242026-03-08: #7741#7,74120262026-08-01: #12840#12,84020262026-10-08: #14665#14,66520262026-10-29: #14720#14,7202026

Rank in USA: #4,723 (Jan 2020) · #5,391 (Jan 2022) · #5,759 (Dec 2022) · #4,332 (Jul 2023) · #4,557 (Jan 2024) · #1,376 (Mar 2026) · #2,621 (Aug 2026) · #2,842 (Oct 2026) · #2,865 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.7×
Free cash flow yield
-5.4%
Net margin
—
Operating margin
—
Return on equity
-25.7%
Liabilities / assets
3.1%
Revenue growth
+14.3%
R&D / revenue
15962.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2019: revenue $12M, net income $3M$12MFY19Fiscal year ending Jun 2020: revenue $0M, net income $-8M$0MFY20Fiscal year ending Jun 2021: revenue $0M, net income $-14M$0MFY21Fiscal year ending Jun 2022: revenue $0M, net income $-18M$0MFY22Fiscal year ending Jun 2023: revenue $0M, net income $-20M$0MFY23Fiscal year ending Jun 2024: revenue —, net income $-22M—FY24Fiscal year ending Jun 2025: revenue —, net income $-38M—FY25Fiscal year ending Jun 2026: revenue —, net income $-46M—FY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2026——$-51M$-46M—
Jun 2025——$-42M$-38M—
Jun 2024——$-22M$-22M—
Jun 2023$0M+14.3%$-19M$-20M-24450.0%
Jun 2022$0M+16.7%$-18M$-18M-26014.3%
Jun 2021$0M-40.0%$-14M$-14M-23133.3%
Jun 2020$0M-99.2%$-8M$-8M-8270.0%
Jun 2019$12M—$3M$3M21.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2026$-17M$0M$-17M$-0.98—
Jun 2025$-24M$0M$-24M$-1.05—
Jun 2024$-19M$0M$-20M$-1.22—
Jun 2023$-18M$0M$-18M$-14.12—
Jun 2022$-16M$0M$-16M$-37.88—
Jun 2021$-13M$0M$-13M$-3.23—
Jun 2020$-8M$0M$-8M$-8.10—
Jun 2019$5M$0M$4M$3.05—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue —, net income $-10M—Dec ’24Three months to Mar 2025: revenue —, net income $-15M—Mar ’25Three months to Jun 2025: revenue —, net income $-9M—Jun ’25Three months to Sep 2025: revenue —, net income $-9M—Sep ’25Three months to Dec 2025: revenue —, net income $-12M—Dec ’25Three months to Mar 2026: revenue —, net income $-12M—Mar ’26Three months to Jun 2026 (from the annual report): revenue —, net income $-13M—Jun ’26Three months to Sep 2026: revenue —, net income $-13M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-13M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Benitec Biopharma Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-51 M
Net income
$-46 M

For year ending June-2026 · source: SEC filing

Balance sheet

Total assets
$183 M
Total liabilities
$6 M
Total equity
$177 M

As of June-2026

Top 91 institutional investors in Benitec Biopharma Inc.#

As of Sep 30, 2026
91 institutions held 33.6 M shares (about 96.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 76.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Benitec Biopharma Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Montanova Capital, LLC11,548,3510 (0.00%)33.11%$115 MNov 16, 2026
2Franklin Templeton Inc2,412,279-609 (-0.03%)6.92%$24 MNov 12, 2026
3Janus Henderson Group Ltd.2,346,047—6.73%$23 MNov 16, 2026
4Adage Capital Partners GP, L.L.C.2,120,6720 (0.00%)6.08%$21 MNov 16, 2026
5Ra Capital Management, L.P.1,850,0000 (0.00%)5.30%$19 MNov 16, 2026
6Nantahala Capital Management, LLC1,677,567-1,299,175 (-43.64%)4.81%$17 MNov 13, 2026
7BlackRock, Inc.1,427,861+20,723 (+1.47%)4.09%$14 MNov 13, 2026
8Infinitum Asset Management, LLC1,259,875+336,869 (+36.50%)3.61%$13 MNov 16, 2026
9Vanguard Capital Management LLC1,035,637+81,104 (+8.50%)2.97%$10 MNov 13, 2026
10Simplify Asset Management Inc.1,002,201-3,356 (-0.33%)2.87%$10 MOct 27, 2026
11Millennium Management LLC760,251-161,048 (-17.48%)2.18%$8 MNov 16, 2026
12Alyeska Investment Group, L.P.750,0000 (0.00%)2.15%$8 MNov 16, 2026
13Geode Capital Management, LLC666,132+54,396 (+8.89%)1.91%$7 MNov 6, 2026
14Balyasny Asset Management L.P.649,954-549 (-0.08%)1.86%$6 MNov 16, 2026
15Silverarc Capital Management, LLC443,109-236,717 (-34.82%)1.27%$4 MNov 12, 2026
16State Street Corp427,515+49,542 (+13.11%)1.23%$4 MNov 12, 2026
17Ameriprise Financial Inc392,991-8,254 (-2.06%)1.13%$4 MNov 16, 2026
18Citadel Advisors LLC271,278+189,812 (+233.00%)0.78%$3 MNov 16, 2026
19MYDA Advisors LLC260,000+10,000 (+4.00%)0.75%$3 MNov 13, 2026
20Schonfeld Strategic Advisors LLC235,525+168 (+0.07%)0.68%$2 MNov 16, 2026
21Vanguard Fiduciary Trust Co198,678+37,683 (+23.41%)0.57%$2 MNov 13, 2026
22Goldman Sachs Group Inc193,550+15,509 (+8.71%)0.55%$2 MNov 16, 2026
23Northern Trust Corp191,849+13,415 (+7.52%)0.55%$2 MNov 16, 2026
24AWM Investment Company, Inc.187,9770 (0.00%)0.54%$2 MNov 13, 2026
25Vanguard Portfolio Management LLC146,389+2,879 (+2.01%)0.42%$1 MNov 13, 2026
Show all 91: investors 26 to 91
Institutional investors 26 to 91 in Benitec Biopharma Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26UBS Group AG109,954-15,477 (-12.34%)0.32%$1 MNov 10, 2026
27Walleye Capital LLC77,984New0.22%$1 MNov 13, 2026
28Wellington Management Group LLP71,196New0.20%$1 MNov 16, 2026
29Charles Schwab Investment Management Inc70,918+67 (+0.09%)0.20%$1 MNov 16, 2026
30MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.67,485+22,379 (+49.61%)0.19%$1 MNov 16, 2026
31Lion Point Capital, LP62,0000 (0.00%)0.18%$1 MNov 16, 2026
32Bank of New York Mellon Corp59,861-200 (-0.33%)0.17%$1 MNov 5, 2026
33Bank Of America Corp /de/52,580+36,609 (+229.22%)0.15%$1 MNov 16, 2026
34Atom Investors LP48,290-301 (-0.62%)0.14%$0 MNov 16, 2026
35Cantor Fitzgerald, L. P.46,659-46,659 (-50.00%)0.13%$0 MNov 16, 2026
36Morgan Stanley42,893+23,317 (+119.11%)0.12%$0 MNov 13, 2026
37Nuveen, LLC33,403+5,064 (+17.87%)0.10%$0 MNov 10, 2026
38Woodline Partners LP29,118New0.08%$0 MNov 16, 2026
39XTX Topco Ltd28,147New0.08%$0 MNov 16, 2026
40Rhumbline Advisers27,795+1,553 (+5.92%)0.08%$0 MNov 10, 2026
41Quadrature Capital Ltd26,302+10,931 (+71.11%)0.08%$0 MNov 13, 2026
42AQR Capital Management LLC25,051+2,570 (+11.43%)0.07%$0 MNov 16, 2026
43Canada Pension Plan Investment Board23,700+6,500 (+37.79%)0.07%$0 MNov 16, 2026
44Russell Investments Group, Ltd.22,314-106,656 (-82.70%)0.06%$0 MNov 6, 2026
45Point72 Asset Management, L.P.22,211New0.06%$0 MNov 16, 2026
46American Century Companies Inc20,531New0.06%$0 MNov 12, 2026
47Price T Rowe Associates Inc /MD/18,5280 (0.00%)0.05%$0 MNov 16, 2026
48Deutsche Bank AG\18,161-2,659 (-12.77%)0.05%$0 MNov 6, 2026
49Martingale Asset Management L P16,1500 (0.00%)0.05%$0 MNov 12, 2026
50MetLife Investment Management, LLC15,4240 (0.00%)0.04%$0 MNov 16, 2026
51Creative Planning15,327New0.04%$0 MNov 2, 2026
52Prudential Financial Inc14,808New0.04%$0 MNov 16, 2026
53EntryPoint Capital, LLC14,405-643 (-4.27%)0.04%$0 MNov 13, 2026
54Vanguard Global Advisers, LLC12,858+4,198 (+48.48%)0.04%$0 MNov 13, 2026
55Jpmorgan Chase & Co10,496+1,500 (+16.67%)0.03%$0 MNov 12, 2026
56Invesco Ltd.10,251-734 (-6.68%)0.03%$0 MNov 12, 2026
57UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC9,872New0.03%$0 MNov 16, 2026
58Barclays PLC8,317+4,902 (+143.54%)0.02%$0 MNov 6, 2026
59GAMMA Investing LLC8,044+83 (+1.04%)0.02%$0 MOct 8, 2026
60FMR LLC6,812+1,596 (+30.60%)0.02%$0 MNov 10, 2026
61Police & Firemen's Retirement System of New Jersey6,8060 (0.00%)0.02%$0 MNov 9, 2026
62BNP Paribas Financial Markets4,871+1,489 (+44.03%)0.01%$0 MNov 12, 2026
63New York State Common Retirement Fund4,3270 (0.00%)0.01%$0 MNov 17, 2026
64Wells Fargo & Company/mn4,280-13,662 (-76.15%)0.01%$0 MNov 16, 2026
65Tower Research Capital LLC (TRC)2,804+132 (+4.94%)0.01%$0 MNov 16, 2026
66Jones Financial Companies Lllp2,417+250 (+11.54%)0.01%$0 MNov 13, 2026
67Legal & General Group Plc2,1310 (0.00%)0.01%$0 MNov 16, 2026
68Global Retirement Partners, LLC1,624New0.00%$0 MNov 10, 2026
69Ameritas Investment Partners, Inc.1,4770 (0.00%)0.00%$0 MNov 13, 2026
70Royal Bank Of Canada1,100+464 (+72.96%)0.00%$0 MNov 16, 2026
71Citigroup Inc1,039-8,812 (-89.45%)0.00%$0 MNov 4, 2026
72Allworth Financial LP551+513 (+1350.00%)0.00%$0 MNov 17, 2026
73Sterling Capital Management LLC437+28 (+6.85%)0.00%$0 MOct 22, 2026
74California State Teachers Retirement System2720 (0.00%)0.00%$0 MNov 13, 2026
75Farther Finance Advisors, LLC243+223 (+1115.00%)0.00%$0 MOct 8, 2026
76US Bancorp \de\234+140 (+148.94%)0.00%$0 MNov 5, 2026
77Arax Advisory Partners227-22 (-8.84%)0.00%$0 MNov 12, 2026
78Fifth Third Bancorp1400 (0.00%)0.00%$0 MNov 5, 2026
79PNC Financial Services Group, Inc.96-138 (-58.97%)0.00%$0 MNov 6, 2026
80Group One Trading LLC890 (0.00%)0.00%$0 MNov 10, 2026
81Caitong International Asset Management Co., Ltd25+16 (+177.78%)0.00%$0 MOct 29, 2026
82EverSource Wealth Advisors, LLC22-8 (-26.67%)0.00%$0 MNov 4, 2026
83Covestor Ltd21New0.00%$0 MOct 30, 2026
84SJS Investment Consulting Inc.18+16 (+800.00%)0.00%$0 MOct 26, 2026
85True Wealth Design, LLC18-5 (-21.74%)0.00%$0 MOct 13, 2026
86Root Financial Partners, LLC18New0.00%$0 MOct 21, 2026
87Essential Partners LLC16New0.00%$0 MOct 14, 2026
88SBI Securities Co., Ltd.8New0.00%$0 MOct 22, 2026
89Provenance Wealth Advisors, LLC8New0.00%$0 MOct 30, 2026
90Rothschild Investment LLC5-9 (-64.29%)0.00%$0 MNov 10, 2026
91Osaic Holdings, Inc.10 (0.00%)0.00%$0 MNov 12, 2026

Mutual funds holding Benitec Biopharma Inc.#

75 funds hold shares worth $64 M (about 14.6% of the company). Since their previous reports 44 added shares and 15 sold, buying $9 M net.
Mutual funds holding Benitec Biopharma Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Simplify Health Care ETFSimplify Asset Management Inc.1.01 M$13 M2.9%3.8%+77%Jun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.995,152$12 M2.9%1.0%no changeJul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.649,542$9 M1.9%<0.01%+3.5%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors533,504$7 M1.5%<0.01%+19%Jun 30, 2026
🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc.357,531$4 M1.0%0.17%no changeJul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.281,899$4 M0.81%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC233,034$3 M0.67%<0.01%+21%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors188,332$3 M0.54%0.02%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC130,966$2 M0.38%<0.01%+0.4%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.99,969$1 M0.29%<0.01%+36%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors71,527$1 M0.21%0.06%+47%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.51,745$1 M0.15%<0.01%+22%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC41,853$1 M0.12%<0.01%+26%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC42,298$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC38,625$0 M0.11%<0.01%+8.9%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC28,102$0 M0.08%0.02%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC28,339$0 M0.08%<0.01%+23%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC21,271$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC24,190$0 M0.07%<0.01%+41%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.19,000$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.18,030$0 M0.05%0.01%+34%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.12,014$0 M0.03%<0.01%+59%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors11,699$0 M0.03%<0.01%−92%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC13,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation11,300$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.11,078$0 M0.03%<0.01%−17%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.11,064$0 M0.03%<0.01%+12%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC10,208$0 M0.03%0.06%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC9,458$0 M0.03%0.01%+67%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.9,001$0 M0.03%<0.01%−14%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC10,191$0 M0.03%<0.01%+21%Jul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC8,964$0 M0.03%<0.01%+3.0%Jul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company8,025$0 M0.02%<0.01%+37%May 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.7,730$0 M0.02%<0.01%+1.3%May 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.6,600$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC5,664$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC4,817$0 M0.01%0.03%+41%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS4,779$0 M0.01%<0.01%+29%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC4,317$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC3,666$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC3,552$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC4,027$0 M0.01%0.01%+6.5%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,864$0 M0.01%<0.01%+3.7%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.3,347$0 M<0.01%<0.01%+24%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,251$0 M<0.01%<0.01%+62%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,974$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,763$0 M<0.01%<0.01%+59%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,721$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC2,338$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC2,496$0 M<0.01%<0.01%+56%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,040$0 M<0.01%<0.01%+96%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,040$0 M<0.01%<0.01%+96%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC2,312$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,698$0 M<0.01%0.01%+43%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,698$0 M<0.01%<0.01%+42%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,890$0 M<0.01%<0.01%+51%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,477$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,636$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION1,500$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,274$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC1,176$0 M<0.01%<0.01%−92%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,267$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,212$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC938$0 M<0.01%<0.01%+82%Jun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC821$0 M<0.01%<0.01%−36%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC912$0 M<0.01%<0.01%+42%May 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC751$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC633$0 M<0.01%<0.01%−1.1%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC725$0 M<0.01%<0.01%−21%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC714$0 M<0.01%<0.01%−22%May 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC616$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.442$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC493$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.127$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC95$0 M<0.01%<0.01%−93%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 75 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Benitec Biopharma Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$2.4 M
12 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$2.4 M
open market only
Insiders on file
7
since
$20.0 M$0Nov 2024: bought $417 K (4 trades), sold $0 (0 trades)Nov 24Dec 2024: bought $930 K (6 trades), sold $0 (0 trades)DecMar 2025: bought $11.9 M (6 trades), sold $0 (0 trades)MarNov 2025: bought $20.0 M (2 trades), sold $0 (0 trades)NovDec 2025: bought $2.4 M (12 trades), sold $0 (0 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Benitec Biopharma Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed J. Kevin BuchiDirectorGift-51,813——52,097Form 4
filed Aaron CowenDirector, 10% ownerBuyindirect+65,800$13.44$884 K9.70 MForm 4
filed Aaron CowenDirector, 10% ownerBuyindirect+11,587$13.44$156 K1.85 MForm 4
filed Aaron CowenDirector, 10% ownerBuyindirect+14,320$13.10$188 K9.63 MForm 4
filed Aaron CowenDirector, 10% ownerBuyindirect+2,516$13.10$33 K1.84 MForm 4
filed Aaron CowenDirector, 10% ownerBuyindirect+42,600$12.85$547 K9.62 MForm 4
filed Aaron CowenDirector, 10% ownerBuyindirect+7,400$12.85$95 K1.83 MForm 4
filed Averill Madison Master Fund, Ltd.10% ownerBuyindirect+16,650$12.08$201 K9.58 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Benitec Biopharma Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.0 M
5.8% of shares · 11.3 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 10,166 shares at $8.80
  • : 8,366 shares at $8.65
  • : 2,366 shares at $8.50
  • : 285 shares at $8.11
  • : 49,715 shares at $8.99

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Benitec Biopharma Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2026; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-5.4%Free cash flow is -5.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.98 vs -1.05Diluted EPS -0.98 in fiscal 2026 against -1.05 the year before (report's currency).
    • ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2026 against -$14 M in 2021.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-33.2%-33.2% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities34.0×Current ratio 34.02 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year28.6%Diluted shares up 28.6% in fiscal 2026.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Benitec Biopharma Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Benitec Biopharma Inc.: statements by fiscal year
PeriodTrendFY 2026to Jun 30, 2026FY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019
Income statement
Revenue——00.10.10.10.112
Research and development23181613117.03.04.6
General and administrative28237.06.46.66.55.64.6
Operating expenses5142221918148.49.6
Operating income−51−42−22−19−18−14−8.32.6
Other non-operating income (expense)5.63.80.7−0.5−0.4−0.30.00.0
Income tax0———————
Net income attributable to shareholders−46−38−22−20−18−14−8.32.6
Earnings per share, basic-0.98-1.05-1.22r-14.12-37.88r-3.23-8.103.05
Earnings per share, diluted-0.98-1.05-1.22r-14.12-37.88r-3.23-8.103.05
Shares, weighted average (basic)473618r1.40.5r4.3——
Shares, weighted average (diluted)473618r1.40.5r4.31.00.9
Balance sheet
Cash and cash equivalents18098512.54.1209.816
Other current assets1.60.60.51.20.70.8r0.90.5
Current assets18299523.74.8211119
Property, plant and equipment0.20.10.20.10.20.40.40.5
Right-of-use (leased) assets0.70.90.30.50.80.8r0.4—
Total assets183100524.56.0211219
Accounts payable0.90.21.41.10.40.30.31.5
Current liabilities5.31.84.94.02.51.41.12.6
Lease liabilities (non-current)0.30.500.30.600.2—
Total liabilities5.62.35.04.33.11.41.32.6
Retained earnings−274−228−190−168−148−130−117−109
Shareholders' equity17797470.22.9201017
Total liabilities and equity183100524.56.0211219
Shares outstanding342610r1.7r0.5r8.21.10.9
Cash-flow statement
Depreciation and amortization0.10.10.10.10.20.20.20.2
Share-based compensation26170.80.50.90.60.20.7
Cash from operating activities−17−24−19−18−16−13−7.54.8
Capital expenditure−0.1−0.0−0.2−0.0−0.0−0.2−0.1−0.4
Cash from investing activities−0.1−0.0−0.2−0.0−0.0−0.2−0.1−0.4
Shares issued10430—18—262.3—
Cash from financing activities99706816—231.8—
Exchange-rate effect on cash—————0.5−0.1−0.6
Change in cash824748−1.6−1610.0——
Report10-K10-K10-K/A10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Benitec Biopharma Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 8 subsidiaries on file.

Benitec Biopharma Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office5 subsidiaries—
🇦🇺 Australia1 office2 subsidiaries—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Benitec Biopharma Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$6.5 M
Dr. Jerel A
Other top executives, average
$4.9 M
the CEO earned 1.3× this
$100 invested is now
$330
Benitec Biopharma Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Dr. Jerel A$6.5 M$9.5 M$4.9 M$330
2025Dr. Jerel A$25.9 M$26.7 M$6.2 M$289
2024Dr. Jerel A$3.2 M$4.3 M$1.4 M$172

Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026

Events at Benitec Biopharma Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • Financial statements withdrawnFiling

Financial statements withdrawn 1 · Auditor changed 2 · Directors and officers 5 · Material agreement 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

Benitec Biopharma Inc.: events reported to the SEC
FiledWhat happenedFiling
Auditor changed8-K
Auditor changed8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Financial statements withdrawn8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K/A
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Benitec Biopharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$40 MPrivate placement after listing$10 to $50 million17equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Benitec Biopharma Inc. compares in Biotechnology

  • Market cap$307 M · higher than 51% of 726
  • Revenue growth14.3% · higher than 57% of 438
  • Price / book1.7× · lower than 62% of 534
  • FCF yield-5.4% · higher than 71% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Benitec Biopharma Inc.🇺🇸$307 M——+14.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending June-2026
Balance sheet:
As of June-2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Benitec Biopharma Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Benitec Biopharma Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Benitec Biopharma Inc.? Suggest a correction